Prostate cancer patients with germline BRCA2 mutations exhibit poorer survival outcomes compared to noncarriers, irrespective of whether they receive surgery or radiotherapy as radical treatment.14, 72. This evidence concerns the gene BRCA2 and prostate carcinoma.